STOCK TITAN

Aktis Oncology (AKTS) director Form 3 shows stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Aktis Oncology director Ken Herrmann filed an initial Form 3 reporting his beneficial ownership in the company mainly through stock options to buy common stock.

The filing lists six stock option grants with exercise prices from $0.08 to $18.00 per share and expiration dates between November 23, 2030 and January 7, 2036. Options covering 6,571 and 19,714 shares have vested in full, while other grants, including 26,285, 64,399 and 10,514 underlying shares, vest in monthly installments tied to his continuous service. A grant covering 18,933 shares is scheduled to vest in full on January 8, 2027. All reported options are held directly.

Positive

  • None.

Negative

  • None.
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Herrmann Ken

(Last) (First) (Middle)
C/O AKTIS ONCOLOGY, INC.
17 DRYDOCK AVENUE, SUITE 17-401

(Street)
BOSTON MA 02210

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
01/08/2026
3. Issuer Name and Ticker or Trading Symbol
Aktis Oncology, Inc. [ AKTS ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (1) 11/23/2030 Common Stock 6,571 $0.08 D
Stock Option (Right to Buy) (2) 04/14/2031 Common Stock 19,714 $1.91 D
Stock Option (Right to Buy) (3) 11/15/2032 Common Stock 26,285 $3.66 D
Stock Option (Right to Buy) (4) 06/30/2034 Common Stock 64,399 $4.95 D
Stock Option (Right to Buy) (5) 12/09/2034 Common Stock 10,514 $10.66 D
Stock Option (Right to Buy) (6) 01/07/2036 Common Stock 18,933 $18 D
Explanation of Responses:
1. These options have vested in full.
2. These options have vested in full.
3. 25% of the original number of shares subject to the option vested on November 1, 2023, and 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.
4. Beginning on May 13, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.
5. Beginning on October 9, 2024, 1/48th of the original number of shares subject to the option vested or shall vest in monthly installments, subject to the Reporting Person's continuous service through each vesting date, inclusive.
6. The number of shares subject to the option shall vest in full on January 8, 2027, subject to the Reporting Person's continuous service through such vesting date.
Remarks:
Exhibit 24 - Power of Attorney
/s/ Ken Herrmann 01/08/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
AKTIS ONCOLOGY INC

NASDAQ:AKTS

AKTS Rankings

AKTS Latest News

AKTS Latest SEC Filings

AKTS Stock Data

1.11B
17.65M
Bare Printed Circuit Board Manufacturing
Telephone & Telegraph Apparatus
Link
US
HUNTERSVILLE